ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia.
 PMID: 29408943       2018       PloS one
Result: Among 48 HIV co-infected subjects analyzed, 31.3% (15) of them developed 3TC/ETV resistance at YMDD RT motif due to rtM204V/I+rtL180M and/or rt<
Discussion: Moreover, with a proportional HBeAg positive and negative status, 29.3% of HIV co-infected patients included in the current study were reported to have 3TC/ETV resistance due to rtM204V/I+rtL180M+rtV173L mutant gene variants.


  2'-Fluoro-6'-methylene carbocyclic adenosine and its phosphoramidate prodrug: A novel anti-HBV agent, active against drug-resistant HBV mutants.
 PMID: 29406612       2018       Medicinal research reviews
Abstract: In vitro, these molecules have demonstrated significant activity against LMV/entecavir (ETV) triple mutants (L180M + S202G + M204V).


  Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.
 PMID: 29315352       2018       PloS one
Method: As previously described, we used the Mutation Reporter Tool (MRT) software (http://hvdr.bioinf.wits.ac.za/mrt/) to look for HBV resistance-associated mutations (RAMs) in the Polymerase catalytic domain represented by major RAMs (A181T/V/S, A194T, M204V/I/S and N236T) and compensatory RAMs (I169T, V173L,
Result: The analysis of HBV strains for the S/Pol gene by the MRT online software showed that of the major RAMs, M204V/I was the most frequent (4/10, 40%), followed by its compensatory RAMs; L180M (3/10, 30%) and V173L (2/10, 20%).


  Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016).
 PMID: 29119303       2018       Virus genes
Abstract: For single-base mutations, rtL180M and rtA181V increased gradually during the past seven years, while rtM204I/V and rtN236T decreased after 2015.
Abstract: Frequencies of rtL180M and rtA181T/V increased gradually in the past seven years, to which we should pay more attention.
Abstract: Moreover, single-base mutation rtA181V and multi-base mutations (rtL180M + M204I


  HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy.
 PMID: 28303969       2017       Scientific reports
Result: Direct sequencing of the PCR amplified RT domain of HBV/D from 16 LMV-failed patients demonstrated the presence of well-known LMV resistance mutations, rtM204V/I, rtL180M, rtS202G, rtL80I and rtA181T, either singly or in combinations.
Result: For those LMV- failed patients whose HBV carried either rtM204V + rtL180M or rtM204I + rt


  HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
 PMID: 27167598       2017       Antiviral therapy
Discussion: Although there were differences in genotype, the dominant pattern of resistance among treatment-experienced patients with mutated strains, (rtM204V + rtL180M), was similar between the European multi-center study (29%) and the present study in Ghana (47.6%).
Discussion: In our study, twenty (95.2%) of the 21 patients had at least one mutation that may confer clinical resistance to both telbivudine (rtM204V/I) and 3TC (rt180M + rtM204V/I, rtV173L + rtL180M + rt PMID: 27354181       2017       Antiviral therapy
Abstract: Despite the finding that rtL180M and rtM204V/I were higher among ART-experienced individuals, the overall prevalence of DRMs (48.0% versus 36.4%) showed no significance difference among antiretroviral therapy (ART) status.
Abstract: Lamivudine selected DRMs, that is, rtL180M (29.3%) and rtM204V/I (29.3%) and rtV173L (15.5%) were more prevalent in HBV-HIV-coinfected individuals but absent in HBV-monoinfected individuals.
Abstract: RESULTS: In 34 out of 161 study subjects (21.1%) HBV drug resistance mutations (DRM


  Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010-2014).
 PMID: 28017671       2017       Journal of global antimicrobial resistance
Abstract: M204I, N236T and L180M+M204V+V173L/S202G were the most common substitutions for l-nucleoside (3TC and LdT), ADV and ETV genotypic resistant phenotypes, respectively.


  Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.
 PMID: 28103819       2017       BMC gastroenterology
Abstract: Seven patients (14.9%) exhibited genotypic resistance mutations (M204I +/- L180M) during the virologic breakthrough.
Result: Of these patients, genotypic resistance mutations to Telbivudine (M204I +/- L180M) were detected in seven during the virologic breakthrough.


  Predominance of Hepatitis B Virus Genotype A Among Treated HIV Infected Patients Experiencing High Hepatitis B Virus Drug Resistance in Nairobi, Kenya.
 PMID: 28316253       2017       AIDS research and human retroviruses
Abstract: Five subjects had rtV173L, rtL180M, and rtM204V and one with rtL180M and rtM204V major mutations.



Browser Board

 Co-occurred Entities




   Filtrator